Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6N ins/del promoter polymorphism (rs3834129) in breast cancer

Gene

Volumn 505, Issue 1, 2012, Pages 176-179

  Hashemi, Mohammad ^a,b   Eskandari Nasab, Ebrahim ^b   Fazaeli, Aliakbar ^b   Rezaei, Hamzeh ^b   Mashhadi, Mohammad Ali ^b   Arbabi, Farshid ^b   Taheri, Mohsen ^c  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Caspase 8; Polymorphism

Indexed keywords

CASPASE 8; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BI DIRECTIONAL POLYMERASE CHAIN REACTION ALLELE SPECIFIC AMPLIFICATION; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDEL MUTATION; IRAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; PROMOTER REGION; REPRODUCIBILITY;

ADULT; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CASPASE 8; GENOTYPE; HUMANS; INDEL MUTATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 84863878850     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.05.043     Document Type: Article

References (30)

1. Catucci I., et al. The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Breast Cancer Res. Treat. 2011, 125:855-860.
2. Chatterjee K., Williamson A.L., Hoffman M., Dandara C. CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer. J. Med. Virol. 2011, 83:630-636.
3. Cybulski C., et al. A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res. Treat. 2008, 112:367-368.
4. De Vecchi G., et al. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Res. Treat. 2009, 113:607-608.
5. Frank B., et al. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res. Treat. 2008, 111:139-144.
6. George G.P., Mandal R.K., Kesarwani P., Sankhwar S.N., Mandhani A., Mittal R.D. Polymorphisms and haplotypes in caspases 8 and 9 genes and risk for prostate cancer: a case-control study in cohort of North India. Urol. Oncol. 2011, http://dx.doi.org/S1078-1439(10)00247-4 [pii]10.1016/j.urolonc.2010.08.027.
7. Ghavami S., et al. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 2009, 46:497-510.
8. Haiman C.A., Garcia R.R., Kolonel L.N., Henderson B.E., Wu A.H., Le Marchand L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat. Genet. 2008, 40:259-260. (author reply 260-251).
9. Hashemi M., Kroczak T.J. Apoptosis and autoimmune disease. Curr. Med. Chem. Anti Inflamm. Anti Allergy Agents 2005, 4:429-437.
10. Hashemi M., Chitayat S., Ande S.R., Chazin W.J. Apoptosis-inducing activity of the S100A8/A9 heterodimer. Curr. Med. Chem. Anti Inflamm. Anti Allergy Agents 2009, 8:318-328.
11. Hashemi M., et al. Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet. Mol. Res. 2010, 9:333-339.
12. Hashemi M., et al. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTT1, GSTM1, and GSTP1) and susceptibility to nonalcoholic fatty liver disease in Zahedan, southeast Iran. DNA Cell Biol. 2012, 31:672-677.
13. Hashemi M., et al. Association of polymorphisms in glutamate-cysteine ligase catalytic subunit and microsomal triglyceride transfer protein genes with nonalcoholic fatty liver disease. DNA Cell Biol. 2011, 30:569-575.
14. Hashemi M., Moazeni-Roodi A., Bahari A., Taheri M. A tetra-primer amplification refractory mutation system-polymerase chain reaction for the detection of rs8099917 IL28B genotype. Nucleosides Nucleotides Nucleic Acids 2012, 31:55-60.
15. Ho T., Wei Q., Sturgis E.M. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007, 29:682-699.
16. Li C., et al. The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. Cancer Prev. Res. (Phila.) 2010, 3:246-253.
17. Liamarkopoulos E., et al. Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. Gastric Cancer 2011, 14:317-321.
18. Liu B., et al. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol. Carcinog. 2010, 49:75-84.
19. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495.
20. Ma X., Zhang J., Liu S., Huang Y., Chen B., Wang D. Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer. Gynecol. Oncol. 2011, 122:554-559.
21. Sergentanis T.N., Economopoulos K.P. Association of two CASP8 polymorphisms with breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 2010, 120:229-234.
22. Srivastava K., Srivastava A., Mittal B. Caspase-8 polymorphisms and risk of gallbladder cancer in a northern Indian population. Mol. Carcinog. 2010, 49:684-692.
23. Sun T., et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat. Genet. 2007, 39:605-613.
24. Theodoropoulos G.E., et al. Polymorphisms of Caspase 8 and Caspase 9 gene and colorectal cancer susceptibility and prognosis. Int. J. Colorectal Dis. 2011, 26:1113-1118.
25. Umar M., Upadhyay R., Kumar S., Ghoshal U.C., Mittal B. CASP8 -652 6N del and CASP8 IVS12 -19G>A gene polymorphisms and susceptibility/prognosis of ESCC: a case control study in northern Indian population. J. Surg. Oncol. 2011, 103:716-723.
26. Wang M., Zhang Z., Tian Y., Shao J. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin. Cancer Res. 2009, 15:2567-2572.
27. Wang Y.X., Zhao L., Wang X.Y., Liu C.M., Yu S.G. Role of Caspase 8, Caspase 9 and Bcl-2 polymorphisms in papillary thyroid carcinoma risk in Han Chinese population. Med. Oncol. 2011, 10.1007/s12032-011-0121-8.
28. Yang M., et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin. Cancer Res. 2008, 14:3230-3236.
29. Yin M., Yan J., Wei S., Wei Q. CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. Carcinogenesis 2010, 31:850-857.
30. Zhu J., et al. Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol. Carcinog. 2010, 49:810-817.